Strategies for AE Management with Tucatinib in Breast Cancer

Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

The use of artificial intelligence led to a higher rate of breast cancer detection as an improvement for mammography screening compared with standard detection methods.

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.